Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Subjects With Relapsed or Refractory B Cell Malignancies

NCT05643742 is registered in ClinicalTrials.gov with CRISPR Therapeutics AG as lead sponsor.

NCT NCT05643742
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05643742 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Subjects With Relapsed or Refractory B Cell Malignancies
Lead sponsor
CRISPR Therapeutics AG
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 10, 2023
Completion date
February 28, 2030
Enrollment
120 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma, b-cell malignancy, chronic lymphocytic leukemia (cll)/small lymphocytic lymphoma (sll), follicular lymphoma, large b-cell lymphoma, mantle cell lymphoma, marginal zone lymphoma, non-hodgkin lymphoma